Forte Biosciences director granted 18,353 RSUs

Forte Biosciences director Shivpreet Singh Kapoor received a grant of 18,353 restricted stock units (RSUs).

Rhea-AI Filing Summary

Forte Biosciences director Shivpreet Singh Kapoor received a grant of 18,353 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Forte Biosciences, Inc. common stock. The award was granted at no exercise price as equity compensation.

All 18,353 RSUs will vest in a single installment on the date of the first annual meeting of stockholders that occurs after May 29, 2026, provided Kapoor continues to serve as a Service Provider under the company’s 2021 Equity Incentive Plan through that date. Following this grant, Kapoor directly holds 18,353 RSUs tied to an equal number of underlying common shares.

Insights

Equity compensation analyst

Director received time-based RSU grant as standard equity compensation.

The filing shows director Shivpreet Singh Kapoor received 18,353 RSUs in Forte Biosciences at an exercise price of $0.00, a typical structure for restricted stock units used in director and executive compensation plans.

The RSUs vest 100% on the first annual stockholder meeting after May 29, 2026, contingent on continued service as a Service Provider under the 2021 Equity Incentive Plan. This is a single time-based vesting event, and no remaining derivative positions are reported in this filing.

Insider Trade Summary

Grant/Award: 18,353 shares

Grant/Award 1 txn

Insider Kapoor Shivpreet Singh

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	18,353	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 18,353 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
2. F2. Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

Key Figures

RSUs granted: 18,353 RSUs Exercise price: $0.00 per RSU Underlying shares: 18,353 shares +1 more

4 metrics

RSUs granted 18,353 RSUs Grant to director on May 29, 2026

Exercise price $0.00 per RSU Restricted stock unit grant

Underlying shares 18,353 shares Common stock underlying RSUs

Holdings after grant 18,353 RSUs Total RSUs held following transaction

Key Terms

Restricted Stock Units, contingent right, Service Provider, 2021 Equity Incentive Plan, +1 more

5 terms

Restricted Stock Units financial

"Forte Biosciences director Shivpreet Singh Kapoor received a grant of 18,353 restricted stock units (RSUs)."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each RSU represents a contingent right to receive one share of Forte Biosciences, Inc. common stock."

Service Provider financial

"Subject to the Reporting Person's continuing as a Service Provider through such date, the RSUs will vest."

2021 Equity Incentive Plan financial

"Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent of the RSUs will vest."

vest financial

"One hundred percent of the RSUs will vest on the date of the first annual meeting of stockholders after May 29, 2026."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Forte Biosciences (FBRX) report for Shivpreet Singh Kapoor?

Forte Biosciences reported that director Shivpreet Singh Kapoor received a grant of 18,353 restricted stock units. Each RSU represents a contingent right to receive one share of Forte Biosciences common stock, granted as equity compensation at a zero exercise price.

How many RSUs did Shivpreet Singh Kapoor receive from Forte Biosciences (FBRX)?

Kapoor received 18,353 restricted stock units from Forte Biosciences. These RSUs correspond to 18,353 underlying shares of common stock and represent a non-cash equity award intended to align director compensation with shareholder interests through future share delivery.

When do Shivpreet Singh Kapoor’s Forte Biosciences (FBRX) RSUs vest?

All 18,353 RSUs vest on the date of the first annual meeting of stockholders after May 29, 2026. Vesting is conditional on Kapoor’s continued status as a Service Provider under Forte Biosciences’ 2021 Equity Incentive Plan through that meeting date.

What does each RSU granted to Shivpreet Singh Kapoor by Forte Biosciences (FBRX) represent?

Each RSU represents a contingent right to receive one share of Forte Biosciences common stock. Shares are only delivered if vesting conditions are met, tying Kapoor’s compensation to future service and the company’s ongoing equity value rather than immediate cash payment.

Does Forte Biosciences (FBRX) Form 4 show any stock sales by Shivpreet Singh Kapoor?

The Form 4 shows no stock sales by Kapoor. It reports only an acquisition via a grant of 18,353 restricted stock units, coded as a grant or award transaction, with no corresponding disposals or open-market sales in the disclosed data.

How many shares does Shivpreet Singh Kapoor hold after this Forte Biosciences (FBRX) RSU grant?

After the RSU grant, Kapoor is reported as directly holding 18,353 restricted stock units. These RSUs are linked to 18,353 underlying shares of Forte Biosciences common stock, deliverable upon satisfaction of the stated vesting and continued-service requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:39 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kapoor Shivpreet Singh

(Last) (First) (Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BUILDING 6

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/29/2026		A		18,353		(2)	(2)	Common Stock	18,353	$0	18,353	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

2. Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

	/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)